Human Papilloma Virus - Research

Human Papilloma Virus - A review.

Human papilloma virus infection remains a great source of morbidity and mortality. Progress in understanding the structure of human papilloma virus and its pathogenesis has led to a wide variety of possible new treatment modalities to combat human papilloma virus related disease. Most human papilloma virus infections (whether high risk or low risk) resolve without any medical intervention. Persistent or progressive disease, however, remains difficult to treat. Although currently available therapies have proved efficacious and tolerable in the treatment of nongenital and genital warts, no single therapy is uniformly effective in eradicating persistent human papilloma virus infection.ÿ Cytodestructive methods, such as cryotherapy, remain the primary treatment modality for nongenital warts. Immune response modifiers, such as imiquimod, currently show the greatest promise in treating human papilloma virus induced anogenital lesions, both with respect to complete response and in preventing recurrence. Human papilloma virus infection is one of the most common sexually transmitted diseases in the world, and cervical cancer still causes significant morbidity and mortality. Pap smear tests have greatly reduced the incidence and mortality of cervical cancer in developed countries. Additional research will focus on primary and secondary prevention strategies. Vaccines against high-risk human papilloma virus types are promising modalities currently under investigation to prevent human papilloma virus infections and possibly to treat them. Study Information from PubMed

Human Papilloma Viruses - Risk factors for genital human papilloma virus (HPV) DNA in men resemble those found in women: a study of male attendees at a Danish STD clinic.

OBJECTIVES: Genital infection with certain types of human papilloma virus (HPV)
is the most important risk factor for cervical cancer. The male sexual partner
is supposed to be the vector of the infection. However, the knowledge of risk
factors for genital human papilloma virus DNA in men is limited. The objective of this paper is to study the risk factors for human papilloma virus infection in men and to compare them with those found in women, including the study of whether there are different risk profiles for oncogenic and non-oncogenic human papilloma virus types. METHODS: From a sexually transmitted diseases (STD) clinic in Denmark, 216 men were consecutively included. A personal interview was done and material for genital human papilloma virus DNA detection was obtained with swabs. Human papilloma virus DNA was detected by polymerase chain reaction (PCR).ÿ Odds ratios (OR) for human papilloma virus as well as for oncogenic and non-oncogenic types separately were computed with a 95% confidence interval (CI) by means of unconditional multiple logistic regresssion. RESULTS: The most important predictors of any human papilloma virus were lifetime number of sex partners (OR = 4.3; 95% CI 1.4 to 13.1 for 25-39 v 1-9 partners), young age, and being uncircumcised. The most important risk factor for oncogenic human papilloma virus types was lifetime number of partners, whereas number of partners in the past year and ever having genital warts were risk factors for the non-oncogenic human papilloma virus types. Young age predicted risk of both oncogenic and non-oncogenic human papilloma virus types. CONCLUSIONS: Most risk factors for human papilloma virus DNA detection in men resemble those found in women. As in women, the risk factor profile for the oncogenic human papilloma virus types was different from that of the non-oncogenic human papilloma virus types. Study Information from PubMed.